STML - Stemline Therapeutics EPS beats by $0.12 misses on revenue November, 07 2019 05:19 PM Stemline Therapeutics Inc. Stemline Therapeutics (NASDAQ:STML): Q3 GAAP EPS of -$0.34 beats by $0.12.More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...